Recent studies have shown the presence of IL-21+ T cells surrounded by T cells expressing IL-13 and IL-4R in the skin of AD patients, which confirms the effectiveness of AD treatment with JAK1 inhibitors such as abrocitinib, baricitinib, and updacitinib [68,69]. Here, JAK1 is linked to Alzheimer disease.